Physician

Promila Dhanuka, M.D.

According to 2025 Medicare claims, Promila Dhanuka, M.D. (NPI: 1225094469) practices hematology/oncology in the Redding, CA market, with the plurality of this provider's patient population coming from Shasta, CA. This provider's primary affiliated billing organization is DOCS MEDICAL GROUP INC (NPI: 1063457620; TIN: 204809365) and primary practice location at 96001-2531.

Dhanuka's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 770 traditional Medicare patients, billed 354,220 HCPCS/CPT codes, and received $2,687,630 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,143 prescription claims across 202 beneficiaries totaling $2,848,870 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 87 claims. Open Payments data shows 39 records totaling $770. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,032,757 and ending at $2,687,630. Concurrently, Part D prescription costs have risen steadily, from $1,331,350 to $2,848,870. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	362	52,955	$1,032,757
2016	480	134,134	$1,343,513
2017	588	180,517	$1,837,802
2018	626	193,672	$1,959,565
2019	643	156,801	$1,538,230
2020	591	189,151	$1,521,525
2021	582	166,363	$1,143,468
2022	650	166,876	$979,635
2023	750	251,685	$1,894,435
2024	770	354,220	$2,687,630

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	123	578	$1,331,350
2016	141	711	$1,764,843
2017	145	920	$2,365,461
2018	146	1,001	$2,514,283
2019	164	1,006	$3,268,857
2020	147	1,064	$2,373,756
2021	142	1,066	$2,751,765
2022	162	1,212	$3,885,387
2023	174	1,026	$3,080,817
2024	202	1,143	$2,848,870

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	42	136	$51,128
2016	30	116	$34,151
2017	44	181	$31,262
2018	26	195	$16,322
2019	22	144	$13,886
2020	22	75	$6,335
2021	24	70	$4,719
2022	N/R	76	$2,474
2023	36	94	$15,641
2024	28	87	$2,009

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	233	233	$166
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	343	678	$141
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	654	2,524	$95
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	175	618	$49
J1100	Injection, dexamethasone sodium phosphate, 1 mg	147	8,251	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	45	1,260	$734,218
Revlimid	Lenalidomide	20	560	$427,646
Jakafi	Ruxolitinib Phosphate	25	750	$403,240
Lenalidomide	Lenalidomide	25	700	$379,373
Calquence	Acalabrutinib Maleate	15	450	$234,596

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	12	31	$923
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	16	24	$433
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	12	$403
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$251

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	39	$770	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Promila Dhanuka, M.D.?

Tedicare shows public-source Medicare data for Promila Dhanuka, M.D. (NPI 1225094469), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Promila Dhanuka, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Promila Dhanuka, M.D.?

Promila Dhanuka, M.D. is linked to DOCS MEDICAL GROUP INC (billing NPI 1063457620) in the available physician profile data.

Does Promila Dhanuka, M.D. have Open Payments data?

Promila Dhanuka, M.D. has 39 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.